AxoGen Stock Surges 29%: Q3 Beat and a Guidance Raise to $290 Million

AxoGen (NASDAQ: AXGN) stock surged about 29% on Wednesday, October 28, 2026, after the nerve-repair company beat third-quarter estimates and raised its full-year revenue guidance to at least $290 million. Revenue rose 26% to $75.8 million and adjusted earnings came in well ahead of Wall Street expectations, making AxoGen one of the day's biggest gainers.

What happened with AxoGen's Q3 earnings?

AxoGen reported third-quarter earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. That compares with earnings of $0.12 per share a year earlier and represents an earnings surprise of about 50%.

Revenue told the same story. The company posted $75.83 million for the quarter ended September 2026, up from $60.08 million a year ago and ahead of consensus estimates. Zacks noted AxoGen has now topped consensus revenue estimates four times over the last four quarters, and topped earnings estimates twice in that span.

Why is AxoGen stock blowing up today?

The beat alone would have helped. The guidance raise is what turned a good quarter into a surge. AxoGen lifted its full-year 2026 revenue outlook to at least $290 million, up from at least $279 million previously and above the $285.6 million consensus. That implies growth of at least 29% for the year.

Importantly, the raise was not only about an acquisition. At least $7 million of the $290 million comes from BioCircuit, which AxoGen bought on October 1. Even without it, the core business is now guided to at least $283 million — so the organic outlook rose too, not just the headline number.

Trading reflected that distinction. Shares jumped roughly 27% to 29% during Wednesday's session, ranking AxoGen among the top gainers on U.S. exchanges, alongside other healthcare names lifted by earnings and clinical news that day.

What drove the growth inside the quarter?

Demand for AxoGen's nerve-repair portfolio was broad. Breast revenue grew more than 50%, according to coverage of the results, continuing a trend also seen in the second quarter. Commercial payer coverage for its Avance nerve graft now reaches about 96% of U.S. covered lives, which reduces a key barrier to wider use.

Profitability improved on an adjusted basis as well. Adjusted EBITDA margin rose to 17.7% from 15.4% a year earlier, even as gross margin eased to 74.8% from 76.6%. In other words, the company grew fast while keeping its high-margin profile broadly intact — the combination investors in medtech growth stocks look for.

What are the key facts?

Q3 EPS: $0.21, versus $0.14 expected and $0.12 a year ago.

Q3 revenue: $75.8 million, up 26.2% year over year, ahead of expectations.

New 2026 guidance: Revenue of at least $290 million, up from at least $279 million, versus $285.6 million consensus.

Core guidance: At least $283 million excluding at least $7 million from BioCircuit.

Stock move: Up about 29% on Wednesday, October 28, 2026.

Sources: Zacks on AxoGen's Q3 beat, TIKR on the surge and guidance raise, and Seeking Alpha on the $290 million outlook.

What's next for AxoGen?

The next test is execution against a higher bar. With guidance now at least $290 million, investors will watch whether fourth-quarter revenue tracks toward the roughly $80 million analysts have pencilled in, and whether breast and core nerve-repair growth can sustain this pace into 2027.

AxoGen also has a November 9 call focused on prostate — a market it plans to start building in 2027 — which could give investors a first detailed look at the next growth leg beyond its current indications. For now, Wednesday's move is a straightforward earnings story: a clear beat, a real guidance raise, and growth that came from the core business as well as a deal. This post reports what happened and why markets reacted; it is not a recommendation to buy, sell, or hold any security.

Frequently Asked Questions

Why did AxoGen stock surge 29% today?

AxoGen beat Q3 estimates — $0.21 EPS versus $0.14 expected on $75.8 million in revenue — and raised full-year 2026 revenue guidance to at least $290 million, above consensus.

What were AxoGen's Q3 2026 results?

Revenue rose 26.2% to $75.83 million from $60.08 million a year ago, and adjusted earnings were $0.21 per share, up from $0.12 a year earlier.

What is AxoGen's new full-year guidance?

At least $290 million in 2026 revenue, including at least $7 million from BioCircuit and at least $283 million from the core business.

What does AxoGen do?

AxoGen is a regenerative-medicine company focused on peripheral nerve repair, best known for its Avance nerve graft, with growing use in areas including breast reconstruction.